Rapamycin (Sirolimus) and ALS (Amyotrophic Lateral Sclerosis): What PubMed Studies Show

By Insight Swarm Research Team, Medical Advisor: Nikhil Joshi, MD, FRCPC

Rapamycin (Sirolimus) and ALS (Amyotrophic Lateral Sclerosis): What PubMed Studies Show

PubMed is the primary database of biomedical literature maintained by the National Library of Medicine. This page describes what PubMed-indexed research reveals about Rapamycin (Sirolimus) in the context of ALS (Amyotrophic Lateral Sclerosis). This is a research summary — not medical advice. Consult your neurologist or ALS specialist.

Volume of Available Research

As of 2026, PubMed contains dozens of relevant publications when searching for "Rapamycin (Sirolimus)" combined with "ALS (Amyotrophic Lateral Sclerosis)". The current evidence level derived from this literature is: Strong preclinical longevity data; established clinical use; PEARL trial studying longevity use

Types of Studies Available

Given the scientific interest in this combination, the published literature includes a range of study types:

  • In vitro (cell culture) studies: Laboratory investigations of Rapamycin (Sirolimus) effects on ALS-relevant cell lines
  • In vivo (animal) studies: Preclinical models examining effects on disease pathways
  • Review articles: Systematic reviews and meta-analyses synthesizing available evidence
  • Clinical studies: Human data from case reports, cohort studies, or clinical trials

How to Search PubMed Yourself

To find the most current and complete literature, use these PubMed search strategies:

  • Basic search: Rapamycin (Sirolimus) ALS (Amyotrophic Lateral Sclerosis)
  • Advanced search: (Rapamycin (Sirolimus)[Title/Abstract]) AND (ALS (Amyotrophic Lateral Sclerosis)[Title/Abstract])
  • Filter by article type: Select "Clinical Trial" to focus on human studies
  • Sort by: Most Recent to see latest publications

Interpreting PubMed Results

When reviewing PubMed studies for Rapamycin (Sirolimus) and ALS, key considerations include:

  • Study design hierarchy: RCTs > cohort studies > case-control > case reports > animal studies > cell culture
  • Sample size: Small studies (n<50) should be interpreted cautiously
  • Conflict of interest: Check funding sources
  • Replication: Single studies should not change treatment decisions

Medical Disclaimer: This page summarizes published research and is not medical advice. Never start, stop, or change any treatment based on information found online. Always consult qualified healthcare professionals before making treatment decisions.

Get a personalized AI-generated research report at insightswarm.ai.

Frequently Asked Questions

How many PubMed studies exist on Rapamycin (Sirolimus) for ALS?

The exact count changes as new research is published. Search pubmed.ncbi.nlm.nih.gov for 'Rapamycin (Sirolimus) AND ALS (Amyotrophic Lateral Sclerosis)' to get the current count. The evidence level from available literature is: Strong preclinical longevity data; established clinical use; PEARL trial studying longevity use.

Are there PubMed clinical trial results for Rapamycin (Sirolimus) in ALS?

To find clinical trial publications: go to PubMed, search 'Rapamycin (Sirolimus) ALS', then use the 'Article type' filter to select 'Clinical Trial'. Some clinical data exists for this combination.

Can I access the full text of Rapamycin (Sirolimus) + ALS studies for free?

Many NIH-funded studies are available free via PubMed Central (PMC). For paywalled articles, try: the author's institution page, ResearchGate, or emailing the corresponding author directly. Some patients also access papers through their hospital library or university networks.